Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

Background: We aim to analyze the efficacy and safety of Venetoclax (Ven) added to cladribine + cytarabine + granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG ± Ida/Mito) regimen as a salvage treatment of relapsed/refractory acute myeloid leukemia (RR-AML). Methods: A...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Zhang, Zhao Yin, Zurong Yao, Dan Xu, Xuejie Jiang, Xiaqi Nie, Dandan Chen, Hongsheng Zhou, Pengcheng Shi, Hui Liu, Qifa Liu, Guopan Yu
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207251319603
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/20406207251319603

Similar Items